Get the Stockscreener App
573.44
2.54%
-14.94
United Therapeutics Corp stock is traded at $573.44, with a volume of 347.77K.
It is down -2.54% in the last 24 hours and up +9.38% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$588.38
Open:
$593.65
24h Volume:
347.77K
Relative Volume:
0.71
Market Cap:
$25.13B
Revenue:
$3.18B
Net Income/Loss:
$1.33B
P/E Ratio:
20.55
EPS:
27.9001
Net Cash Flow:
$1.04B
1W Performance:
-0.73%
1M Performance:
+9.38%
6M Performance:
+32.53%
1Y Performance:
+101.40%
1-Day Range:
$571.65
$593.65
1-Week Range:
$571.65
$593.65
52-Week Range:
$272.12
$607.89
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
573.44 | 25.13B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
17.55 | 55.44B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.72 | 51.61B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.68 | 43.06B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.02 | 37.28B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics CEO Rothblatt sells $5.57 million in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $5.57 million in stock - Investing.com
United Therapeutics to present research data at heart and lung conference - Investing.com
11 new studies on lung transplants, PH and xenotransplants head to ISHLT - Stock Titan
UTHR PE Ratio & Valuation, Is UTHR Overvalued - Intellectia AI
United Therapeutics (NASDAQ:UTHR) CFO Sells $5,771,800.00 in Stock - MarketBeat
Rothblatt, United Therapeutics CEO, sells $5.48 million in stock - Investing.com
Rothblatt, United Therapeutics CEO, sells $5.48 million in stock By Investing.com - Investing.com Canada
United Therapeutics (NASDAQ:UTHR) Director Christopher Patusky Sells 1,000 Shares - MarketBeat
United Therapeutics (UTHR) director sells 1,000 shares after option exercise - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) CFO sells 10,000 shares after option exercise - Stock Titan
[144] UNITED THERAPEUTICS Corp SEC Filing - Stock Titan
Martine Rothblatt Sells 75 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (UTHR) CEO trades shares under Rule 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) EVP & General Counsel sells 8,300 shares after option exercise - Stock Titan
UNITED THERAPEUTICS CORPORATION (UTHR) - MSN
Rothblatt, United Therapeutics CEO, sells $5.5 million in stock By Investing.com - Investing.com Australia
Rothblatt, United Therapeutics CEO, sells $5.5 million in stock - Investing.com
United Therapeutics (UTHR) CEO pre-plans 9,500-share option exercise and sale - Stock Titan
CFO of United Therapeutics (UTHR) exercises 10k options, sells 10k shares - Stock Titan
Assetmark Inc. Sells 10,952 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock - Investing.com UK
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock By Investing.com - Investing.com India
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
UTHR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
United Therapeutics (NASDAQ:UTHR) Stock Rating Upgraded by Raymond James Financial - MarketBeat
UNITED THERAPEUTICS (UTHR) CEO sells 9,500 shares after option exercise under 10b5-1 plan - Stock Titan
Analyst Ratings Update: United Therapeutics (UTHR) Current Price Target Raised | UTHR Stock News - GuruFocus
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Raymond James initiates United Therapeutics stock coverage with outperform rating - Investing.com Australia
Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock - Investing.com Australia
Raymond James initiates United Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa
Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock By Investing.com - Investing.com South Africa
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
United Therapeutics’ liver device gets FDA regenerative therapy status - Investing.com
Bioengineered liver for acute liver failure gets key FDA designation - Stock Titan
James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) CFO Sells $5,615,000.00 in Stock - MarketBeat
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock By Investing.com - Investing.com Australia
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock By Investing.com - Investing.com Canada
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock - Investing.com
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
United Therapeutics rises on positive study for cornerstone drug. Why shares could run even higher - MSN
Perpetual Ltd Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):